Clinical Trials Provider Soars, Clears Buy Point On Solid Q2 Results
Shares of Iqvia (IQV) surged past a buy point Tuesday after the provider of clinical research services beat second-quarter estimates and raised guidance. Revenue climbed 8.7% to $4.368 billion year over year, while adjusted earnings increased 12% to $3.15 a share. Analysts, on average, expected revenue of $4.310 billion. The consensus earnings estimate was $3.03 per share, with the highest…
Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
Related news
Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics
12/04/2025 Biotech stocks and research shares diverged Thursday after reports suggested the FDA will soon require just one pivotal study.
12/04/2025 Biotech stocks and research shares diverged Thursday after reports suggested...
Comments 0
Leave a Reply
Your email address will not be published. Required fields are marked *
Business & Finance
Explore AllWhats New
View All
‘Spider-Man: Brand New Day’ Credits Scene Explained: Will Tom Holland Return in ‘Avengers: Doomsday’ or ‘Secret Wars’?
Trump says Morocco named Tiznit-Dakhla highway after him: Why it matters
Pacific island nation Nauru officially changes name to ‘Naoero’
Hamas says it has agreed to disarm after Trump announces Board of Peace plan
Anthropic says Claude AI hacked three firms during cyber tests
Anthropic Says Claude Hacked 3 Organizations During Cybersecurity Tests
Nepal’s PM urges calm as three people killed after Hindu-Muslim unrest
Anthropic says its own AI models breached three companies during security tests
‘Stuart Fails to Save the Universe’ Producers on Episode 2’s Surprise Kaley Cuoco Cameo As an Alternate Penny
